Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVCCOV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-escalation study

• Published in: EClinicalMedicine Vol. 38; p. 100989
• Main Authors: Hsieh, Szu-Min, Liu, Wang-Da, Huang, Yu-Shan, Lin, Yi-Jiun, Hsieh, Erh-Fang, Lian, Wei-Cheng, Chen, Charles, Janssen, Robert, Shih, Shin-Ru, Huang, Chung-Guei, Tai, I-Chen, Chang, Shan-Chwen
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.08.2021; Elsevier
• Subjects: Internal Medicine; Research Paper

This was a phase 1, dose-escalation open-label trial to evaluate the safety and immunogenicity of MVCCOV1901, a SARS-CoV-2 S-2P protein vaccine adjuvanted with aluminum hydroxide and CpG 1018. Between September 28 and November 13 2020, 77 participants were screened. Of these, 45 healthy adults from...